Cardiovascular and oncologic outcomes of nivolumab + ipilimumab vs. pembrolizumab in malignant melanoma: A global real-world data analysis
Department
Internal Medicine
Document Type
Conference Proceeding
Publication Title
Journal of Clinical Oncology
Conference Name
American Society of Clinical Oncology (ASCO) Annual Meeting
Conference Date
2025-05-30 - 2025-06-03
First Page
e21538
DOI
10.1200/JCO.2025.43.16_suppl.e21538
Volume
43
Issue
16_suppl
Publication Date
6-1-2025
Recommended Citation
Dalal, S., Khan, A. W., Ishaq, M., Mufarrih, S. M., Rehman, T., Khan, A., Salzberg, M. P., & Hussein, A. (2025). Cardiovascular and oncologic outcomes of nivolumab + ipilimumab vs. pembrolizumab in malignant melanoma: A global real-world data analysis. Journal of Clinical Oncology, 43 (16_suppl), e21538. https://doi.org/10.1200/JCO.2025.43.16_suppl.e21538
COinS